Olfactory Training in COVID-19 Associated Loss of Smell
Primary Purpose
COVID-19, Hyposmia
Status
Not yet recruiting
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
Sniffin' sticks Duftquartett
Sponsored by
About this trial
This is an interventional treatment trial for COVID-19
Eligibility Criteria
Inclusion Criteria:
- The subject is aged over 18 years;
- confirmed diagnosis of COVID-19 at least three months ago (history of positive PCR-testing required);
- post-infectious COVID-19 related olfactory dysfunction persisting for at least three months with abnormal Sniffin' sticks test (<13/16 items correct in the identification part);
- the patient is willing to undergo odor training over 12 weeks;
- written ICF is obtained.
Exclusion Criteria:
- History of olfactory dysfunction prior to COVID-19 infection due to other conditions e.g. status post traumatic brain injury, Parkinson's disease, allergic rhinitis, etc.;
- Nasal pathology not related to COVID-19 in the systematic otorhinolaryngological examination including endoscopy.
- the participant is pregnant
Sites / Locations
- Medical University of Innsbruck
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
olfactory training group
no olfactory training with natural history of the disease
Arm Description
12 weeks of olfactory traiing with Sniffin' sticks "Duftquartett".
natural history of the disease
Outcomes
Primary Outcome Measures
primary endpoint
change of scores in odor identification and discrimination between baseline and Week 12
Secondary Outcome Measures
Full Information
NCT ID
NCT05421221
First Posted
June 15, 2022
Last Updated
June 15, 2022
Sponsor
Medical University Innsbruck
1. Study Identification
Unique Protocol Identification Number
NCT05421221
Brief Title
Olfactory Training in COVID-19 Associated Loss of Smell
Official Title
A Randomized Controlled Trial of the Effectiveness of Olfactory Training on Loss of Smell Related to COVID-19 (SMELL)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 1, 2022 (Anticipated)
Primary Completion Date
August 1, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University Innsbruck
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Olfactory dysfunction (OD) like hyposmia or anosmia has been realized as a common symptom or even cardinal sign of the disease and can be persisting after recovering.
There are two different hypotheses on the pathogenesis of OD in past COVID-19: The central hypothesis, which speculates on neurotrophic abilities on olfactory receptors in the neuroepithelium, and the peripheral hypothesis, which speculates on damage of the sensory olfactory epithelium.
Potential treatment strategies aim for the unique neural plasticity of the olfactory system and its potential for recovery.
Clinical studies and case reports have shown a promising effect of olfactory training (OT) by frequent sniffing and/or exposure to odors 2-4 times a day for several weeks.
The main objective of the study is to assess the effects of olfactory training in patients with COVID-19 related OD on:
objective olfactory testing with the Sniffin' sticks test (identification and discrimination) (primary endpoint),
subjective OD and its impact on the daily life (key secondary endpoint),
other clinical scales and questionnaires referring to OD-related mood and quality of life (other secondary endpoint),
gender differences in COVID-19 related OD (exploratory endpoint). Approach / methods OT will be performed twice a day with a 4-odor training set for 12 weeks. Effects of OT on COVID-19 related OD will be measured with objective and subjective efficacy variables.
The sense of smell is an important function for social relationships and is therefore a challenging clinical problem with few proven therapeutic options.
With this new approach, we want to investigate a possible simple treatment for an impedimental symptom of COVID-19, but also learn more about the pathomechanism of post-infectious OD.
To our knowledge, this will be the first study comparing patients with COVID-19 associated OD with and without OT in clinical outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19, Hyposmia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
olfactory training group
Arm Type
Experimental
Arm Description
12 weeks of olfactory traiing with Sniffin' sticks "Duftquartett".
Arm Title
no olfactory training with natural history of the disease
Arm Type
No Intervention
Arm Description
natural history of the disease
Intervention Type
Device
Intervention Name(s)
Sniffin' sticks Duftquartett
Intervention Description
4-odor training set over 12 weeks with Sniffin' sticks "Duftquartett"
Primary Outcome Measure Information:
Title
primary endpoint
Description
change of scores in odor identification and discrimination between baseline and Week 12
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The subject is aged over 18 years;
confirmed diagnosis of COVID-19 at least three months ago (history of positive PCR-testing required);
post-infectious COVID-19 related olfactory dysfunction persisting for at least three months with abnormal Sniffin' sticks test (<13/16 items correct in the identification part);
the patient is willing to undergo odor training over 12 weeks;
written ICF is obtained.
Exclusion Criteria:
History of olfactory dysfunction prior to COVID-19 infection due to other conditions e.g. status post traumatic brain injury, Parkinson's disease, allergic rhinitis, etc.;
Nasal pathology not related to COVID-19 in the systematic otorhinolaryngological examination including endoscopy.
the participant is pregnant
Facility Information:
Facility Name
Medical University of Innsbruck
City
Innsbruck
State/Province
Tirol
ZIP/Postal Code
6020
Country
Austria
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Beatrice Heim, MD PhD
Phone
+4351250481128
Email
beatrice.heim@i-med.ac.at
12. IPD Sharing Statement
Learn more about this trial
Olfactory Training in COVID-19 Associated Loss of Smell
We'll reach out to this number within 24 hrs